Animal Venoms as a Source of Therapeutics: Insights into Anticancer, Cardiovascular, Antimicrobial, Analgesic, Antiparasitic and Emerging Applications

Animal venoms are complex biological secretions that contain peptides, proteins, enzymes and other low-molecular-weight constituents evolved to act with high potency and selectivity on physiological targets. Their toxicity, once viewed primarily as a limitation, has increasingly become a pharmacological advantage when individual molecules are isolated, structurally characterized and redesigned to retain therapeutic activity while reducing unwanted effects. The original manuscript highlighted anticancer, cardiovascular, antimicrobial, analgesic and antiparasitic activities of snake, spider, scorpion and stonefish venoms. This revised review retains those core themes and expands them to include venom composition, mechanisms of action, clinically established venom-inspired medicines, translational barriers, peptide engineering, venomics and emerging computational approaches. Snake venom has contributed to the discovery of bradykinin-potentiating peptides and the development of captopril, while disintegrin-inspired pharmacophores contributed to antiplatelet agents such as eptifibatide and tirofiban. Experimental anticancer research has identified cytotoxins, disintegrins, phospholipases and other components capable of affecting apoptosis, integrin signaling, matrix metalloproteinases, angiogenesis and tumor-cell migration. Spider venom peptides such as lycosin-II demonstrate activity against clinically isolated multidrug-resistant bacteria, although such findings remain preclinical. Scorpion venoms provide ion-channel modulators and analgesic peptide leads; the recently described Buthicyclin illustrates how computational design and peptide cyclization can produce a candidate with analgesic activity in animal models. Stonefish ichthyocrinotoxins represent an emerging area of antiparasitic research. Bee venom, particularly melittin and phospholipase A2, provides additional examples of membrane-active and immunomodulatory molecules with anticancer and antiviral potential. The review emphasizes that promising in-vitro or animal findings should not be equated with clinical efficacy. Major challenges include toxicity, selectivity, immunogenicity, proteolytic instability, manufacturing, formulation, pharmacokinetics and delivery. Recent advances in venomics, mass spectrometry, transcriptomics, structural biology, artificial intelligence and peptide engineering are increasingly addressing these barriers. Overall, animal venoms represent valuable molecular libraries for target discovery and therapeutic lead optimization, but successful translation depends on rigorous mechanistic, pharmacokinetic, toxicological and clinical validation.